絞り込み

18452

広告

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

著者 Long GV , Dummer R , Hamid O , Gajewski TF , Caglevic C , Dalle S , Arance A , Carlino MS , Grob JJ , Kim TM , Demidov L , Robert C , Larkin J , Anderson JR , Maleski J , Jones M , Diede SJ , Mitchell TC
Lancet Oncol.2019 Jun 17 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (27view , 0users)

Full Text Sources

Medical

Research Materials

Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma. In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab versus placebo plus pembrolizumab.
PMID: 31221619 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード